Browse News
Filter News
Found 110 articles
-
Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024
1/22/2024
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024.
-
Wyss Center Appoints Dr. Craig Cook as New Head of Business Development and Licensing
7/10/2023
The Wyss Center, a leading non-profit research center dedicated to innovating and accelerating technologies and therapies for neurological and mental health disorders, is pleased to announce the appointment of Craig Cook, MD, MBA, to the leadership team as Head of Business Development and Licensing.
-
ADR Ratio Change
6/22/2023
Biodexa Pharmaceuticals PLC, a clinical-stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain, announces a ratio change on its American Depositary Receipts from one ADR representing five ordinary shares, to the new ratio of one ADR representing four hundred ordinary shares.
-
Bioasis Provides Corporate Update and Announces Suspension of Operations
6/20/2023
BIOASIS TECHNOLOGIES INC., a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factor and a differentiated, proprietary xB3 ™ platform for delivering therapeutics across the blood-brain barrier and the treatment of central nervous system disorders in areas of high unmet medical need, provided an update on its financial condition and operations.
-
Epsilogen announces significant expansion of management team with three new senior hires
4/26/2023
Epsilogen Ltd, a global leader in the development of novel immunoglobulin E antibodies to treat cancer, announced three new senior hires in what is a significant expansion of their management team.
-
Biodexa Pharmaceuticals PLC Announces Exercise of Pre-Funded Warrants & Issue of Equity - April 05, 2023
4/5/2023
Biodexa Pharmaceuticals PLC announces that it has issued to various investors 7,265,825 new ordinary shares of £0.02 each in the Company, pursuant to exercise notices in respect of 1,453,265 Pre-Funded Warrants received yesterday.
-
Biodexa Pharmaceuticals PLC Announces Exercise of Pre-Funded Warrants & Issue of Equity
4/4/2023
Biodexa Pharmaceuticals PLC announces that it has issued to various investors 24,798,160 new ordinary shares of £0.02 each in the Company, pursuant to exercise notices in respect of 4,959,632 Pre-Funded Warrants received yesterday.
-
Biodexa Pharmaceuticals PLC Announces Issue of Pre-Funded Warrants
4/3/2023
Biodexa Pharmaceuticals PLC announces that, in accordance with the terms of previously issued Pre-Funded Warrants and the associated Price Adjustment Mechanism under the Private Placement, it has issued an additional 10,508,394 Pre-Funded Warrants, calculated by dividing the aggregate subscription amount by 90% of the average of the daily volume weighted average prices of the five trading days prior to the date of this announcement.
-
Biodexa Pharmaceuticals PLC Announces Exercise of Warrants and Issue of Equity - March 30, 2023
3/30/2023
Biodexa Pharmaceuticals PLC announces that it has issued to various investors 6,218,265 new ordinary shares of £0.02 each in the Company, pursuant to exercise notices in respect of 1,243,653 B Warrants received yesterday.
-
Biodexa Pharmaceuticals PLC Announces Exercise of Warrants and Issue of Equity - March 29, 2023
3/29/2023
Biodexa Pharmaceuticals PLC, a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it has issued to various investors 18,636,190 new ordinary shares of £0.02 each in the Company, pursuant to the exercise notices in respect of 1,738,136 A Warrants and 1,989,102 B Warrants received yesterday.
-
Biodexa Pharmaceuticals PLC Announces Exercise of Warrants and Issue of Equity
3/28/2023
Biodexa Pharmaceuticals PLC announces that it has issued to various US investors 7,473,095 new ordinary shares of £0.02 each in the Company, pursuant to the exercise notices in respect of 848,068 A Warrants and 646,551 B Warrants received yesterday.
-
Midatech Pharma PLC Announces R&D Programme Focused on Leptomeningeal Disease
3/27/2023
Midatech Pharma PLC is pleased to announce a new research programme coded MTD217 focusing on developing new therapeutic options for metastatic cancers with high unmet needs.
-
Midatech Pharma PLC Announces Results of General Meeting
3/24/2023
Midatech Pharma PLC is pleased to announce that at the general meeting of the Company held earlier today all resolutions put to the Company's shareholders were duly passed.
-
Midatech Pharma PLC Announces Further re: Notice of General Meeting
3/10/2023
Further to the announcement made on 8 March 2023 providing notice of a general meeting of the Company to be held on 24 March 2023, and the publication and despatch of a circular to shareholders containing notice of the resolutions to be considered at the GM and form of proxy, the Company announces the following corrections to certain typographical errors identified within the Notice and Form of Proxy:
-
Midatech Pharma PLC Announces Closing of $6.0m Private Placement & Broker Change
2/15/2023
Midatech Pharma PLC, a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines, announces the closing of the Private Placement of 10,344,822 Units initially at an issue price of US$0.58 per Unit.
-
Midatech Pharma PLC Announces Receipt of NASDAQ Notice - February 03, 2023
2/3/2023
Midatech Pharma PLC announces that it received written notification from The NASDAQ Stock Market LLC, dated 31 January 2023, stating that the Company is not in compliance with the minimum bid price requirement set forth in NASDAQ's rules for continued listing on The NASDAQ Capital Market.
-
Bioasis Announces AGM Results and Provides Update on Financial Position
2/3/2023
BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”) is pleased to announce that all resolutions were passed by the requisite majority at its annual general meeting (the “Meeting”) held earlier today.
-
Bioasis Technologies Inc. Announces Termination of Arrangement Agreement with Midatech Pharma plc
1/23/2023
BIOASIS TECHNOLOGIES INC today announced that it has terminated the arrangement agreement (the “Arrangement Agreement”) dated December 13, 2022, as amended December 18, 2022, between Bioasis and Midatech Pharma plc (“Midatech”).
-
Midatech Pharma PLC Announces Result of General Meeting
1/23/2023
Midatech Pharma PLC announces that at its General Meeting held at 10.00 a.m. today all ordinary resolutions were carried, but all other resolutions were not passed by shareholders, as set out in the table below.
-
Midatech Pharma PLC Announces Planned Dose Escalation in MTX-110 Phase 1 Study
1/12/2023
Midatech Pharma PLC is pleased to announce that following completion of one month of treatment with MTX-110 in the first patient, its Phase I study of MTX-110 in recurrent glioblastoma will continue with a planned dose escalation following a positive recommendation from the study's Data Safety Monitoring Board.